Coming into focus: the nonovarian origins of ovarian cancer.
about
The miR-200 Family: Versatile Players in Epithelial Ovarian CancerTargeting TBP-Associated Factors in Ovarian CancerThe disparate origins of ovarian cancers: pathogenesis and prevention strategies.Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinomaPathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implicationsA Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier StateThree-dimensional modeling of ovarian cancer.Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci.Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.Spontaneous Transformation of Murine Oviductal Epithelial Cells: A Model System to Investigate the Onset of Fallopian-Derived Tumors.Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.Primary fallopian tube carcinoma: review of MR imaging findingsIn vivo tumor growth of high-grade serous ovarian cancer cell linesPlatelet-Derived Growth Factor in the Ovarian Follicle Attracts the Stromal Cells of the Fallopian Tube Fimbriae.Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma.It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.The chicken model of spontaneous ovarian cancer.SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance.Pathogenesis and heterogeneity of ovarian cancer.Primary fallopian tube carcinoma arising in the setting of chronic pelvic inflammatory disease.Ovarian cancer stem cells: still an elusive entity?Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer.Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma.Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse.Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries.Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian CancerCharacterization of stem cell and cancer stem cell populations in ovary and ovarian tumorsUnfolded protein response, a link between endometrioid ovarian carcinoma and endometriosis: A pilot study
P2860
Q26799353-A996F21A-3CE1-41B9-8FBC-F5BEB7A6852AQ26866045-8D476020-B302-4435-8D61-8A308A61EC19Q30240709-EA55ECBA-098F-4FE8-8398-1A8E82E74AE9Q33728994-7C5748E8-994E-4781-AF79-54352D7B622BQ34501822-5D26534C-121B-494B-A367-1AA5265D3616Q34503833-B0039D45-B351-47D4-AE23-F1648E29A602Q35591610-569BBD32-DABF-4EC6-9E28-4F8AE510FAE3Q35693892-4CA65E54-58BE-4B34-91C3-6CD54D15B481Q35749439-A8CE26F9-6AE6-4809-8F2B-563C32B73CAFQ35859678-4696E050-0502-4E1C-B8DA-F66694AB4D5FQ35897417-05CB48A5-B3F4-4D01-A45E-BA58D53C975CQ35902265-847084D2-689C-49B9-9C18-E3048E682AA4Q35927115-CEB820D7-8263-409D-A191-1296F4FAAAD7Q36068092-9E013B2E-1996-43F0-B739-23C8D5F45A41Q36409618-1E090319-3942-4428-B3C3-E30EE08BD5F1Q36436803-615D4120-09B6-4F37-B32A-4E7F3EA76F8BQ36685324-E840E9D0-A065-4A09-B726-B532A56916F2Q37046171-040CECFD-1208-4F7D-B4C5-3846155ADDA4Q37426775-288CA67F-5337-4B2A-AA52-EE8BDE6B1F06Q37546692-DE65FFEE-569F-4100-AE84-D666F73EDA9DQ37553928-AA698452-3FC2-4EFD-9E0A-F58D20C7704BQ37713683-E7F21156-56A4-460A-8688-942EC3D00D38Q37729033-625EC96C-6908-4420-B508-7B18EF4810DFQ38787442-ACDABDF7-7F83-46A5-8091-705E08837108Q39441988-E9AB5CE8-69E8-4A82-839E-5950E417D8B8Q39711357-3AF44279-22A6-425D-B32E-E39FBEF88EBBQ42379619-B62BC788-80C0-4BC8-8204-BF99A2675C52Q42671513-447DC112-24F2-4BB2-897E-7E2A3CB26563Q47243819-ED1CB591-E76E-4DF8-B892-F6FE507EA1B6Q47581752-F13CEB67-477F-43D4-8F2C-D5E7FDFBE786Q50055585-5E0D5231-5B23-47BC-B12E-0283EFCA4F71Q58704255-FEE0C4F2-DDE3-4547-AFA5-EA720DFEE2B7Q58766995-69D9C4CA-047B-4F26-9DB7-431471CBA319Q58802711-1235E707-97C4-458D-94ED-3DE96C3E964E
P2860
Coming into focus: the nonovarian origins of ovarian cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Coming into focus: the nonovarian origins of ovarian cancer.
@ast
Coming into focus: the nonovarian origins of ovarian cancer.
@en
Coming into focus: the nonovarian origins of ovarian cancer.
@nl
type
label
Coming into focus: the nonovarian origins of ovarian cancer.
@ast
Coming into focus: the nonovarian origins of ovarian cancer.
@en
Coming into focus: the nonovarian origins of ovarian cancer.
@nl
prefLabel
Coming into focus: the nonovarian origins of ovarian cancer.
@ast
Coming into focus: the nonovarian origins of ovarian cancer.
@en
Coming into focus: the nonovarian origins of ovarian cancer.
@nl
P2860
P356
P1433
P1476
Coming into focus: the nonovarian origins of ovarian cancer
@en
P2093
P2860
P304
viii28-viii35
P356
10.1093/ANNONC/MDT308
P478
24 Suppl 8
P577
2013-11-01T00:00:00Z